



# Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions


## SUPPLEMENTARY FIGURES



Supplementary Figure 1: c-MET and VEGFR2 gene and protein expression levels detected during osteoclast A e C. and osteoblast B e D. differentiation. \*(p < 0.05).



Supplementary Figure 2: Effect of cabozantinib treatment on osteoclast viability (MTT assay).



**Supplementary Figure 3: Effect of cabozantinib treatment on osteoblast differentiation and activity.** Representative images of ALP **A.** and Alizarin Red assay **B.** in untreated (DMSO) and treated osteoblasts.